Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ji

Showing results (201-210 of 241) with videos related to

Pageof 25
Sort By:
Zeitschrift Fur Rheumatologie|June 29, 2014
Meta-analysis of SLC22A4 and RUNX1 polymorphisms : Associations with rheumatoid arthritis susceptibilityY H Lee, S-C Bae, J-H Kim, et al.
Journal of Human Hypertension|November 16, 2012
Lack of association between STK39 and hypertension in the Chinese populationJ Xu, L D Ji, L N Zhang, et al.
Canadian Journal of Microbiology|July 27, 1999
Sequence analysis of the Gluconobacter oxydans RecA protein and construction of a recA-deficient mutantY T Liu, C G Chen, D C Chao, et al.
Rheumatology (Oxford, England)|April 21, 2005
Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2J D Ji, H J Kim, Y H Rho, et al.
Journal of Molecular Recognition : JMR|December 1, 1989
Agonist derived molecular probes for A2 adenosine receptorsK A Jacobson, L K Pannell, X D Ji, et al.
Journal of Applied Microbiology|November 7, 2012
Long PCR-RFLP of 16S-ITS-23S rRNA genes: a high-resolution molecular tool for bacterial genotypingY H Zeng, M Koblížek, Y X Li, et al.
ESMO Open|May 13, 2023
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trialsC Mao, D Ji, Y Ding, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2000
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatinK Mishima, A P Mazar, A Gown, et al.
Journal of Medicinal Chemistry|February 2, 1996
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptorsP G Baraldi, B Cacciari, G Spalluto, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 6, 1996
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factorS Y Cheng, H J Huang, M Nagane, et al.
Pageof 25

Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Zeitschrift Fur Rheumatologie|June 29, 2014
Meta-analysis of SLC22A4 and RUNX1 polymorphisms : Associations with rheumatoid arthritis susceptibilityY H Lee, S-C Bae, J-H Kim, et al.
Journal of Human Hypertension|November 16, 2012
Lack of association between STK39 and hypertension in the Chinese populationJ Xu, L D Ji, L N Zhang, et al.
Canadian Journal of Microbiology|July 27, 1999
Sequence analysis of the Gluconobacter oxydans RecA protein and construction of a recA-deficient mutantY T Liu, C G Chen, D C Chao, et al.
Rheumatology (Oxford, England)|April 21, 2005
Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2J D Ji, H J Kim, Y H Rho, et al.
Journal of Molecular Recognition : JMR|December 1, 1989
Agonist derived molecular probes for A2 adenosine receptorsK A Jacobson, L K Pannell, X D Ji, et al.
Journal of Applied Microbiology|November 7, 2012
Long PCR-RFLP of 16S-ITS-23S rRNA genes: a high-resolution molecular tool for bacterial genotypingY H Zeng, M Koblížek, Y X Li, et al.
ESMO Open|May 13, 2023
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trialsC Mao, D Ji, Y Ding, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2000
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatinK Mishima, A P Mazar, A Gown, et al.
Journal of Medicinal Chemistry|February 2, 1996
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptorsP G Baraldi, B Cacciari, G Spalluto, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 6, 1996
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factorS Y Cheng, H J Huang, M Nagane, et al.
Pageof 25